
Once-weekly insulin's longer half-life reshapes the hypoglycemia conversation, and trial data point to a bigger role for CGM in primary care.

Rachael Sood is the Founder and Chief Executive Officer of the Diabetes Collective, the 1st and only Direct Diabetes Service line by an NP in the United States of America. Mrs. Sood has been in practice since 2006, and earned her Masters of Science in Nursing and Advanced practice degrees at Southeastern Louisiana University. She is board certified by the American Academy of Nurse Practitioners and Certification Board for Diabetes Care and Education. Rachael works in a hybrid role as a health care provider and DCES. She is a member of the American Diabetes Association and Louisiana Association of Nurse Practitioners. She was honored as a recipient of the Top 40 Nurses recognized for a Spirit of Excellence and Emerging Leaders by the Louisiana State Nurses Association in 2024 and was recently nominated for CDCES of the year in 2026. Mrs. Sood’s specialty areas include diabetes education on social media where she enjoys being artistic as a Content creator. Her favorite areas of interest include Diabetes technology, Type 1 advocacy, and population health. This year, she is expanding her corporation with the launch of a Diabetes focused infusion service line.

Once-weekly insulin's longer half-life reshapes the hypoglycemia conversation, and trial data point to a bigger role for CGM in primary care.

A nurse practitioner discusses why once-weekly basal insulin matters, who benefits most, and how its starting doses differ from daily insulin.

Rachael Sood, NP-C, CDCES, outlines what the FDA clearance of Control-IQ+ for type 1 diabetes in pregnancy means for primary care practice.


Once-weekly insulin makes injections simpler, boosts adherence, and lets clinics train patients fast—ideal for older adults.

Which patients are most likely to benefit from once-weekly insulin? Early insights on insulin icodec for adults with type 2 diabetes, here.